CRNX
Crinetics Pharmaceuticals, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth -18.2% ·
share flow -9.2% ·
net new positions -20.0%
· formula
Broad distribution: falling shares and fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q1 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 89 | -1 | 71.70M | $2.68B | +5 | −6 |
| Q1 2026 | 93 | +2 | 73.05M | $2.65B | +9 | −7 |
| Q4 2025 | 90 | 0 | 75.54M | $3.52B | n/a | n/a |
| Q3 2025 | 15 | 0 | 56.94M | $2.37B | n/a | n/a |
| Q2 2025 | 12 | 0 | 51.44M | $1.48B | +1 | −1 |
| Q1 2025 | 9 | -2 | 19.08M | $640.10M | +2 | −4 |
| Q4 2024 | 11 | -1 | 21.01M | $1.07B | n/a | −1 |
| Q3 2024 | 11 | -2 | 14.60M | $745.98M | n/a | −2 |
| Q2 2024 | 13 | n/a | 14.80M | $663.11M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wellington Management ✦ | 6.89M | -0.8% | $231.14M | 0.0% | ▼ Trim | 4 | SEC ↗ ×7 |
| 2 | T. Rowe Price ✦ | 5.11M | -5.6% | $171.47M | 0.0% | ▼ Trim | 4 | SEC ↗ ×2 |
| 3 | State Street Global Advisors ✦ (passive) | 3.28M | +9.8% | $110.12M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 4 | Geode Capital Management ✦ (passive) | 2.19M | +4.4% | $73.50M | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 5 | Point72 Asset Management ✦ | 778.40K | -72.1% | $26.11M | 0.1% | ▼ Trim | 4 | SEC ↗ |
| 6 | Fisher Asset Management ✦ | 773.35K | +38.3% | $25.94M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 7 | Citadel Advisors ✦ | 38.55K | +716.4% | $1.29M | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 8 | Marshall Wace ✦ | 9.18K | New | $307,964 | 0.0% | New | 1 | SEC ↗ |
| 9 | Millennium Management ✦ | 6.69K | New | $224,316 | 0.0% | New | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Marshall Wace | $307,964 | 0.0% |
| Millennium Management | $224,316 | 0.0% |
Exited
| Duquesne Family Office | $6.27M | was 0.2% |
| Adage Capital Partners | $3.32M | was 0.0% |
| D. E. Shaw & Co. | $504,960 | was 0.0% |
| AQR Capital Management | $398,712 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 241 holders, 121.45M shares, $4.08B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.